Amandala Neuro

Amandala Therapeutics is a preclinical-stage biotechnology company dedicated to developing first-in-class small molecule therapies for neurodegenerative diseases. The company's primary focus is on addressing protein misfolding and aggregation, specifically targeting the TDP-43 protein which is implicated in the pathogenesis of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). By leveraging deep expertise in protein structural biology and medicinal chemistry, Amandala aims to create disease-modifying treatments that can halt or reverse the progression of devastating neurological conditions. The company's approach involves identifying molecules that can either prevent the formation of toxic aggregates or promote the clearance of existing protein clumps in the brain and spinal cord.